[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370452-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370452-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","response-efficacy-of-pd-1-and-pd-l1-inhibitors-in-salivary-gland-cancers-a-systematic-review-and-meta-analysis","Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers - a systematic review and meta-analysis","","Meta-analysis assessing the efficacy of immune checkpoint inhibitors targeting PD-1 and PD-L1 in salivary gland cancers. Searches in PubMed, Scopus, and Google Scholar (up to 24 February 2024) identified eligible cohort studies and randomized controlled trials, with study quality appraisal and data extraction followed by pooled analysis. Across five cohort studies and three RCTs totaling 532 patients, progression-free survival increased with both PD-1 and PD-L1 inhibitors, with pooled effects supporting improved disease control. Conclusions emphasize potential benefit and the need for further larger RCTs due to heterogeneity.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/response-efficacy-of-pd-1-and-pd-l1-inhibitors-in-salivary-gland-cancers-a-systematic-review-and-meta-analysis/370452/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/response-efficacy-of-pd-1-and-pd-l1-inhibitors-in-salivary-gland-cancers-a-systematic-review-and-meta-analysis/370452.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What question does this systematic review address?","Question",{"text":63,"@type":64},"It evaluates whether PD-1 and PD-L1 inhibitors are effective for treating salivary gland cancers, focusing on treatment efficacy outcomes such as progression-free survival.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were studies selected and analyzed?",{"text":68,"@type":64},"The review searched PubMed, Scopus, and Google Scholar up to 24 February 2024, extracted and screened article full texts, assessed study quality, and registered the protocol on PROSPERO before conducting pooled analyses.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main results for progression-free survival?",{"text":72,"@type":64},"The pooled analysis of cohort studies and RCTs showed increased progression-free survival in patients receiving PD-1 or PD-L1 inhibitors, with pooled effect estimates and 95% confidence intervals reported for each study type.",{"name":74,"@type":61,"acceptedAnswer":75},"What limitations or next steps are noted in the conclusion?",{"text":76,"@type":64},"High heterogeneity across included studies is highlighted, and additional randomized controlled trials with larger sample sizes are recommended to strengthen the evidence.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370452,1790922566,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","TYPE Systematic Review PUBLISHED 02 April 2025  \nDOI 10.3389/fonc.2025.1534343  \nOPEN ACCESS  \nEDITED BY  \nVincent Vander Poorten, KU Leuven, Belgium  \nREVIEWED BY  \nRajdeep Chakraborty, Macquarie University, Australia Jan Paul De Boer,  \nThe Netherlands Cancer Institute (NKI), Netherlands  \n*CORRESPONDENCE  \nNiloofar Deravi  \n [niloofarderavi@sbmu.ac.ir](niloofarderavi@sbmu.ac.ir)[ ](niloofarderavi@sbmu.ac.ir)Masoud Noroozi  \n [2000noroozi@gmail.com](2000noroozi@gmail.com)  \n†These authors have contributed equally to this work  \nRECEIVED 25 November 2024  \nACCEPTED 12 March 2025  \nPUBLISHED 02 April 2025  \nCITATION  \nBabamohamadi Z, Taherkhani A, Yousefzadeh A, Moradi A, Heidari M, Hoseini Nasab ZS, Haghi SM, Afkhami A, Belbasi M, Noroozi M and Deravi N (2025) Response efﬁcacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic review and meta-analysis.  \nFront. Oncol. 15:1534343 .  \ndoi: 10.3389/fonc.2025.1534343  \nCOPYRIGHT  \n© 2025 Babamohamadi, Taherkhani, Yousefzadeh, Moradi, Heidari,  \nHoseini Nasab, Haghi, Afkhami, Belbasi, Noroozi and Deravi. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) .  \nThe use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nResponse efﬁcacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic review and meta-analysis  \nZahra Babamohamadi 1†, Amirreza Taherkhani 2†, Ali Yousefzadeh 2†, Ali Moradi 3, Marziyeh Heidari 4, Zahra Sadat Hoseini Nasab 5, Seyedeh Mona Haghi 6, Ayda Afkhami 7, Mohaddeseh Belbasi 8, Masoud Noroozi 9* and Niloofar Deravi 2*  \n1 Hearing Disorders Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 2Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, 3Center for Translational Medicine, Semmelweis University, Budapest, Hungary, 4 Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran, 5School of Medicine, Mashhad University of Medical Science, Mashhad, Iran, 6Student Research Committee, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran, 7Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran, 8Students Research Committee, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran, 9 Department of Biomedical Engineering, Faculty of Engineering, University of Isfahan, Isfahan, Iran  \nBackground: Salivary gland carcinoma (SGC) is an infrequent malignancy characterized by various pathological subtypes. Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic strategies for several cancers. Evidence suggests that ICIs may be effective against rare neoplasms, including SGC. This meta-analysis evaluated the efﬁcacy of programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors in treating salivary gland cancers.  \nMethod: A thorough search was conducted in PubMed, Scopus, and Google Scholar databases up to 24 February 2024 . The title, abstract, and full text of related articles were extracted and screened, and the quality of the included articles was assessed. The data extracted were then analyzed. The research protocol of this systematic review and meta-analysis was registered on the PROSPERO website.  \nResults: Altogether, a total of ﬁve cohort studies and three randomized controlled trials (RCTs) with a total population of 532 were included in these meta-analyses. These studies were conducted in the USA, Japan, France, and China. The average age of the patients was between 53 and 67 years. Our analyses showed an increase in progression-free survival in the cohort studies and RCTs","cbCaieN2Seuhy53F","https://ap.wps.com/l/cbCaieN2Seuhy53F","pdf",1626456,"English","# Background\n# Method\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What question does this systematic review address?\",\"answer\":\"It evaluates whether PD-1 and PD-L1 inhibitors are effective for treating salivary gland cancers, focusing on treatment efficacy outcomes such as progression-free survival.\"},{\"question\":\"How were studies selected and analyzed?\",\"answer\":\"The review searched PubMed, Scopus, and Google Scholar up to 24 February 2024, extracted and screened article full texts, assessed study quality, and registered the protocol on PROSPERO before conducting pooled analyses.\"},{\"question\":\"What were the main results for progression-free survival?\",\"answer\":\"The pooled analysis of cohort studies and RCTs showed increased progression-free survival in patients receiving PD-1 or PD-L1 inhibitors, with pooled effect estimates and 95% confidence intervals reported for each study type.\"},{\"question\":\"What limitations or next steps are noted in the conclusion?\",\"answer\":\"High heterogeneity across included studies is highlighted, and additional randomized controlled trials with larger sample sizes are recommended to strengthen the evidence.\"}]","Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers - a systematic review and meta-analysis | PDF",1790188580,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61a89445b42a413fae356851ebf61bc8.webp",983,1389,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a8314663560c23112fe65c2af76fbff.webp",982,1388,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9e2b6c0e81d777e813d44b0847924d6.webp",981,1386,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ad3958fb1f41ad881c3d7de0fec5179.webp",980,1385]